Supplement Issue

References

• Citrome L, Volavka J. The promise of atypical anti-psychotics: fewer side effects mean enhanced com-pliance and improved functioning. Postgrad Med 2004;116:49–63.
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. Old versus new: weighing the evi-dence between the first- and second-generation anti-psychotics. Eur Psychiatry 2005;20:7–14.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, etal, for the Clini-cal Antipsychotic Trials of Intervention Effectiveness (CATTE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endo-crinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
   PubMedGoogle Scholar
• Markowitz JS, Brown CS, Moore TR. Atypical antipsy-chotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73–85.
   Google Scholar
• Kinon BJ, Lieberman TA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psy-chopharmacology (Berl) 1996;124:2–33.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thalcore In. Impaired fasting glucose tolerance in first-episode, drug-naïve pa-tients with schizophrenia. Am I Psychiatry 2003;160: 284–9.
   Google Scholar
• Baptista T, DeMendoza S, Beaulieu S, etal. The meta-bolic syndrome during atypical antipsychotic drug treatment: mechanisms and management Metab Syndr Relat Disord 2004;2:290–307.
   Google Scholar
• Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120:18–32.
   PubMed Web of Science ®Google Scholar
• Goldstein LE, Sporn I, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associ-ated with olanzapine treatment. Psychosomatics 1999;40:438–43.
   PubMed Web of Science ®Google Scholar
• Kohen I, Gampel M, Reddy L, et aL Rapidly develop-ing hyperglycemia during treatment with olanzapine. Ann Pharmacother 2008;42:588–91.
   Google Scholar
• Duiverman ML, Cohen D, van Oven W, etal. A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening. Neth I Med 2007;65:346–8.
   Google Scholar
• Cohen D. Atypical antipsychotics and new onset dia-betes mellitus. Pharmacopsychiatry 2004;37:1–11.
   PubMed Web of Science ®Google Scholar
• Clark C, Burge MR. Diabetes mellitus associated with atypical antipsychotic medications. Diabetes Technol 7her 2003;5:669–83.
   PubMedGoogle Scholar
• McCreadie RG. Use of drugs, alcohol, and tobacco by people with schizophrenia: case-control study. Br Psychiaby 2002;191:321–5.
   Google Scholar
• Zimmerman U, Kraus T, Himmerich H, et al. Epide-miology, implications, and mechanisms underlying drug-induced weight gain in psychiatric patients. Psychiat r Res 2003;37:193–220.
   Google Scholar
• Isojarvi III, Laatilcainen fl, Knip M, etal. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579–584.
   PubMed Web of Science ®Google Scholar
• Boehm G, Racoosin JA, Laughren TP, etal. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus state-ment Diabetes Care 2004;27:2088–9.
   Google Scholar
• Citrome L, Volavka J. Consensus development confer-ence on antipsychotic drugs and obesity and diabe-tes: response to consensus statement Diabetes Care 2004;27:2087–8.
   Google Scholar
• Isaac MT, Isaac MB. Consensus development confer-ence on antipsychotic drugs and obesity and diabe-tes: response to consensus statement Diabetes Care 2004;27:2088–90.
   Google Scholar
• Glick ID. Understanding the results of CATTE in the context of the field. CNS Spear 2006;11\(suppl 7):40–7.
   Google Scholar
• Allison DB, Mentore it, Heo M, etal. Antipsychotic-induced weight gain: a comprehensive research syn-thesis. Am J Psychiatry 1999;156:1686–96.
   PubMed Web of Science ®Google Scholar
• Citrome L Efficacy should drive atypical antipsychotic treatment BM/2003;326:283.
   Google Scholar
• Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interac-tions. Curr Drug Metab 2008;9:410–8.
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL Drug-drug interactions associ-ated with second-generation antipsychotics: consid-erations for clinicians and patients. Psychopharmacol Bull 2007;40:77–97.
   PubMed Web of Science ®Google Scholar
• Hughes JR, Hatsukami DK, Mitchell JE, et aL Preva-lence of smoking among psychiatric outpatients. Am,/ Psychiatry 1986;143:993–7.
   PubMed Web of Science ®Google Scholar
• Williams JAC Foulds J. Successful tobacco depen-dence treatment in schizophrenia. Am I Psychiatry 2007;164:222–7.
   Google Scholar
• Dratcu L, Grandison A, McKay G, etal. Clozapine-re-sistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am,/ Ther 2007;14:314–8.
   PubMedGoogle Scholar
• Derenne JL, Baldessarini RT. Clozapine toxicity asso-ciated with smoking cessation: case report. Am J 7her 2005;12:469–71.
   PubMedGoogle Scholar
• Dalack GW, Becks L, Hill E, et al. Nicotine with-drawal and psychiatric symptoms in cigarette smok-ers with schizophrenia. Neuropsychopharmacology 1999;21:195–202.
   PubMed Web of Science ®Google Scholar
• Nussbaum A, Stroup TS. Paliperidone for schizo-phrenia. Cochrane Database Syst Rev 2008;April 16: CD006369.
   Google Scholar
• Goldstein TM, Christoph G, Grimm S, et al. Unique mechanism of action for the antidepressant proper-ties of the atypical antipsychotic quetiapine. Poster presented at: American Psychiatric Association, 160th Annual Meeting; May 19–24, 2007; San Diego, CA. Poster NR336.
   Google Scholar
• Jensen NH, Rodriguiz RM, Caron MG, et al. N- de-sallcylquetiapine, a potent norepinephrine reuptalce inhibitor and partial 5-HT1A agonist as a putative mediator of quetiapine's antidepressant activity. Neu-ropsychopharmacology 2008;33:2303–12.
   PubMed Web of Science ®Google Scholar
• Pira L, Mongeau R, Pani L The atypical antipsychotic quetiapine increases both noradrenaline and dopa-mine release in the rat prefrontal cortex. Eur J Pharma-co/ 2004;504:61–4.
   PubMed Web of Science ®Google Scholar